Cargando…

Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease

BACKGROUND: Inflammatory reaction is an essential factor in the occurrence, development and prognosis of femoropopliteal disease (FPD). The ratio of platelets to lymphocytes (PLR) is a new indicator reflecting platelet aggregation and burden of systemic inflammation. Our study is to explore the asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhen, Yanhua, Chang, Zhihui, Liu, Zhaoyu, Zheng, Jiahe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950933/
https://www.ncbi.nlm.nih.gov/pubmed/31918662
http://dx.doi.org/10.1186/s12872-019-01314-1
_version_ 1783486185060958208
author Zhen, Yanhua
Chang, Zhihui
Liu, Zhaoyu
Zheng, Jiahe
author_facet Zhen, Yanhua
Chang, Zhihui
Liu, Zhaoyu
Zheng, Jiahe
author_sort Zhen, Yanhua
collection PubMed
description BACKGROUND: Inflammatory reaction is an essential factor in the occurrence, development and prognosis of femoropopliteal disease (FPD). The ratio of platelets to lymphocytes (PLR) is a new indicator reflecting platelet aggregation and burden of systemic inflammation. Our study is to explore the association between preoperative platelet-to-lymphocyte ratio (pre-PLR) and 6-month primary patency (PP) after drug-coated balloon (DCB) in FPD. METHODS: There were 70 patients who underwent DCB for FPD contained in the study. According to 6-month PP, patients were divided into group A (PP ≥6 months, n = 54) and group B (PP < 6 months, n = 16). Logistic regression analysis was used to identify potential predictors for 6-month PP after DCB in FPD. A receiver operating characteristic (ROC) curve analysis was used to identify the cut-off value of pre-PLR to predict 6-month PP. RESULTS: Logistic regression analysis showed that pre-PLR (OR: 1.008, 95% CI: 1.001–1.016, P = 0.031) and lesion length > 10 cm (OR: 4.305, 95% CI: 1.061–17.465, P = 0.041) were independently predictive for 6-month PP. The cutoff value of pre-PLR obtained from the ROC analysis was 127.35 to determine 6-month PP with the area of 0.839. Subgroup analysis was conducted based on the cutoff value of pre-PLR. The 6-month PP in the group of pre-PLR < 127.35 was higher than that of pre-PLR ≥ 127.35 group (p < 0.001). CONCLUSIONS: The present study indicated that an elevated pre-PLR was an effective additional indicator for predicting early PP in FPD after DCB.
format Online
Article
Text
id pubmed-6950933
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69509332020-01-09 Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease Zhen, Yanhua Chang, Zhihui Liu, Zhaoyu Zheng, Jiahe BMC Cardiovasc Disord Research Article BACKGROUND: Inflammatory reaction is an essential factor in the occurrence, development and prognosis of femoropopliteal disease (FPD). The ratio of platelets to lymphocytes (PLR) is a new indicator reflecting platelet aggregation and burden of systemic inflammation. Our study is to explore the association between preoperative platelet-to-lymphocyte ratio (pre-PLR) and 6-month primary patency (PP) after drug-coated balloon (DCB) in FPD. METHODS: There were 70 patients who underwent DCB for FPD contained in the study. According to 6-month PP, patients were divided into group A (PP ≥6 months, n = 54) and group B (PP < 6 months, n = 16). Logistic regression analysis was used to identify potential predictors for 6-month PP after DCB in FPD. A receiver operating characteristic (ROC) curve analysis was used to identify the cut-off value of pre-PLR to predict 6-month PP. RESULTS: Logistic regression analysis showed that pre-PLR (OR: 1.008, 95% CI: 1.001–1.016, P = 0.031) and lesion length > 10 cm (OR: 4.305, 95% CI: 1.061–17.465, P = 0.041) were independently predictive for 6-month PP. The cutoff value of pre-PLR obtained from the ROC analysis was 127.35 to determine 6-month PP with the area of 0.839. Subgroup analysis was conducted based on the cutoff value of pre-PLR. The 6-month PP in the group of pre-PLR < 127.35 was higher than that of pre-PLR ≥ 127.35 group (p < 0.001). CONCLUSIONS: The present study indicated that an elevated pre-PLR was an effective additional indicator for predicting early PP in FPD after DCB. BioMed Central 2020-01-09 /pmc/articles/PMC6950933/ /pubmed/31918662 http://dx.doi.org/10.1186/s12872-019-01314-1 Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhen, Yanhua
Chang, Zhihui
Liu, Zhaoyu
Zheng, Jiahe
Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
title Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
title_full Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
title_fullStr Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
title_full_unstemmed Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
title_short Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
title_sort platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950933/
https://www.ncbi.nlm.nih.gov/pubmed/31918662
http://dx.doi.org/10.1186/s12872-019-01314-1
work_keys_str_mv AT zhenyanhua platelettolymphocyteratiopredicting6monthprimarypatencyofdrugcoatedballoonforfemoropoplitealdisease
AT changzhihui platelettolymphocyteratiopredicting6monthprimarypatencyofdrugcoatedballoonforfemoropoplitealdisease
AT liuzhaoyu platelettolymphocyteratiopredicting6monthprimarypatencyofdrugcoatedballoonforfemoropoplitealdisease
AT zhengjiahe platelettolymphocyteratiopredicting6monthprimarypatencyofdrugcoatedballoonforfemoropoplitealdisease